Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Bristol-Myers CEO Pay Surges After Cancer Drug Sales Start Fast

Lamberto Andreotti, chief executive officer of Bristol-Myers Squibb Co. Photographer: Daniel Acker/Bloomberg
Lamberto Andreotti, chief executive officer of Bristol-Myers Squibb Co. Photographer: Daniel Acker/Bloomberg

March 12 (Bloomberg) -- Bristol-Myers Squibb Co. Chief Executive Officer Lamberto Andreotti received a 27 percent increase in total compensation after a new skin cancer drug gained approval and contributed to higher sales and profits.

Andreotti’s total compensation rose to $14.9 million in 2011 from $11.8 million a year earlier, according to a regulatory filing. The pay included a bonus of $4.2 million related to the company’s financial results, share price increase and the start of sales for the melanoma drug Yervoy, according to the filing. Andreotti also received an 11 percent base salary increase to $1.5 million effective April 1, 2011, “to bring him closer to competitive market levels,” the company said in the filing.

The higher pay for Andreotti reflected, among other things, his leadership in “delivering the strong 2011 financial results” such as annual earnings per share of $2.28 that exceeded a target of $2.14 a share and “executing the Yervoy launch,” the company said in the March 9 filing with the U.S. Securities and Exchange Commission.

Bristol-Myers loses patent exclusivity on its best-selling drug Plavix later this year. It is counting on new drugs such as Yervoy to replace the expected reduction in revenue. The melanoma treatment was approved in March 2011 and generated $360 million in sales last year. Bristol-Myers in January agreed to purchase Inhibitex Inc. for $2.5 billion to gain its hepatitis C drug as part of its “string of pearls” strategy to develop new products through acquisitions.

The New York-based drugmaker also ended a one-year salary freeze for all employees in 2011, the company said in the filing.

Bristol-Myers rose less than 1 percent to $33.05 in New York. The company’s shares, which gained 33 percent in 2011, have declined 6.2 percent this year.

Jennifer Mauer, a Bristol-Myers spokeswoman, had no comment beyond the filing.

To contact the reporter on this story: Robert Langreth in New York at rlangreth@bloomberg.net

To contact the editor responsible for this story: Reg Gale at rgale5@bloomberg.net

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.